Chronic Rhinosinusitis Market

Chronic Rhinosinusitis Market

Market Overview

Global Chronic Rhinosinusitis Market was valued at USD 2,132.5 Million in 2019 and is projected to reach USD 3,508.0 Million by 2030, growing at a CAGR of 7.4%. Rising incidence of inflammation of nasal passage mucosa, growing prevalence of chronic asthma and paranasal sinus cases are likely to fuel the growth prospects of the chronic rhinosinusitis market over the forecast period . Nasal obstruction, inflammation of the mucous membranes of the sinuses and nose, facial pain as well as rhinorrhea and loss of smell mainly characterize chronic rhinosinusitis. Treatment associated with chronic rhinosinusitis includes improving sinus outflow, improving mucociliary clearance, and eliminating inflammation and local infection among other associated treatments. In addition, pollutants, fungal infections and allergies are major contributors to the increase in cases of rhinosinusitis. Therefore, the development and production of competent sinusitis drugs are likely to be in great demand for effective treatment of chronic rhinosinusitis.

Market Dynamics

The ultimate goal of effective treatment for chronic rhinosinusitis is to manage associated symptoms in order to improve quality of life. Moreover, the widespread awareness about the symptoms of the target disease across all regions, technological advancements, and increase in the adoption of minimally invasive surgical techniques, among other favorable scenarios, are likely to enhance the growth of the industry. during the forecast period. However, the high cost accompanying the treatment, low inclination towards sinus surgery businesses, and post-surgical risks of sinus treatment might limit the growth of the chronic rhinosinusitis market over the forecast period.

North American region accounted for the largest revenue share in the global chronic rhinosinusitis market in 2019 owing to favourable reimbursement scenarios, growing incidences of chronic asthma and rhinosinusitis symptoms and supportive infrastructure among other factors are likely to propel industry growth in the period 2023-2030.

Market Growth

Rhinosinusitis, including chronic rhinosinusitis, affects a significant portion of the population in the United States, with prevalence rates ranging from 1% to 5%. This indicates that approximately 15 million people experience symptoms of chronic rhinosinusitis. The high prevalence of this condition has a direct impact on the global chronic rhinosinusitis market, and it is expected to drive market growth over the forecast period.

The large number of individuals suffering from chronic rhinosinusitis highlights the substantial patient population that requires effective treatment options. This increased prevalence creates a growing demand for therapies, medications, and medical interventions to address the symptoms and underlying causes of chronic rhinosinusitis.

As healthcare providers and pharmaceutical companies focus on developing innovative treatments and management strategies for chronic rhinosinusitis, the global market for this condition is expected to experience significant growth. The aim is to improve the quality of life for individuals affected by chronic rhinosinusitis by offering better therapeutic options and reducing the burden of the disease.

Considering the substantial number of individuals affected by chronic rhinosinusitis and the potential for improved treatment approaches, the market for this condition is projected to expand steadily in the coming years, driven by the increased prevalence and the growing need for effective interventions.

Industry Trend

In November 2019, SynDermix AG and ISS AG collaborated on a clinical study aimed at evaluating the safety and efficacy of SDX-3101 in adult patients with chronic rhinosinusitis without nasal polyps (CRSsNP). The study focuses on the vibration pattern of SDX-3101, a potential treatment for this condition. The partnership between SynDermix AG and ISS AG demonstrates the commitment to advancing the understanding and treatment options for CRSsNP.

In September 2018, Lyra Therapeutics secured $29.5 million in funding for the development of a medication implant specifically designed for chronic rhinosinusitis. The implant, known as LYR-210, has garnered significant financial support and is currently undergoing a Phase II clinical study. Additionally, Lyra Therapeutics is actively researching and developing its platform for the treatment of other ear, nose, and throat (ENT) disorders.

These developments highlight the ongoing efforts within the medical community to address the challenges associated with chronic rhinosinusitis. The collaboration between SynDermix AG and ISS AG and the funding received by Lyra Therapeutics demonstrate a commitment to advancing treatment options and improving outcomes for patients with chronic rhinosinusitis and related ENT conditions.

Product Outlook:

The product outlook in the industry is categorized into several segments, including Steroids (Topical Nasal Steroids and Systemic Steroids), Nasal Irrigation (Hypertonic and Isotonic Saline Solution, Steroid Nasal Irrigation, and Topical Antibiotic Therapy), Surgical Practices (Ethmoidectomy, Endoscopic Intranasal Procedure, and Others), Antibiotics (Amoxicillin-clavulanate, clindamycin, sulfamethoxazole, and levofloxacin), treatment with macrolides, and antifungal treatment.

In 2019, the antibiotic products category accounted for the largest market share within the industry. Antibiotics play a crucial role in treating various infections and are widely used in the management of sinusitis. However, the Nasal Irrigation products sector is expected to witness the fastest growth, with a projected growth rate of 8.2%. Nasal irrigation has shown increasing efficacy in the treatment of chronic rhinosinusitis, leading to its growing adoption and demand in the market.

These product segments represent diverse treatment options available for addressing sinusitis and related conditions. The dominance of antibiotics and the rapid growth of nasal irrigation products highlight the ongoing efforts to enhance treatment effectiveness and improve patient outcomes in the management of sinusitis.

Disease Outlook:

In 2019, the anatomical differences disease segment had a significant impact on the industry due to the increasing prevalence of rhinosinusitis, chronic asthma, and other sinusitis infections and disorders worldwide. This segment, which focuses on anatomical variations in the nasal and sinus passages, played a major role in shaping the disease outlook within the industry. The disease outlook is categorized into various segments including anatomical differences, nasal tumors, mucosal edema, non-allergic rhinitis, and immune deficiency, among others. These segments encompass a range of diseases and conditions related to the nasal and sinus regions. The prominence of the anatomical differences disease segment in 2019 highlights the importance of addressing anatomical variations and related conditions in the healthcare industry to improve patient outcomes and provide effective treatments.

Regional Outlook:

Due to a rise in cases of chronic asthma and rhinosinusitis in the area, Asia Pacific achieved the highest CAGR of 8.3% in 2019 and is expected to continue to see high growth rates during the projection period. Additionally, the region's expansion is being primarily driven by factors such as increased pollution, excessive smoking, and environmental changes, particularly in nations like China and India.

Due to major technological advancements, a notable breakthrough in treatment methods, advantageous reimbursement regulations, prospective investment possibilities, and other favourable circumstances, North America led the chronic rhinosinusitis market in 2019.

Key Market Estimates & Forecast

• The anatomical differences disease segment accounted for the largest market share of approximately 37.5% owing to the increase in the prevalence of the target disease across the globe. However, the immunodeficiency disease segment in disease outlook recorded the highest CAGR of 7.1% in 2019
• Hospital pharmacy segment in distribution channel outlook led the market with significant market share followed closely by retail pharmacy segment due to availability of prescribed drugs and devices to treat chronic rhinosinusitis
• Antibiotics segment held the largest market share of 41.6% in 2019 and is expected to dominate the industry over the forecast period, owing to the high employability of antibiotics and their efficacy in effective treatment chronic rhinosinusitis
• North America accounted for the largest market revenue in 2019 with a significant market share of 37.2% due to favorable reimbursement policies, high prevalence of the target disease and advances technologies, among other encouraging scenarios
• The Asia-Pacific region recorded the highest CAGR of 8.3% in 2019. Regions like India and China, among other countries, offer substantial growth prospects such as a large pool of patients, potential investment opportunities and increased prevalence of the target disease due to excessive air pollution leading to symptoms of chronic asthma and rhinosinusitis among other factors

Post COVID Impact

The post-COVID impact on the Chronic Rhinosinusitis (CRS) market has been significant, presenting both challenges and opportunities. With the pandemic exacerbating sinus-related complications in many individuals, the demand for effective treatments has surged. As a result, the CRS market has witnessed a notable growth in research and development activities, leading to the emergence of innovative therapies. Additionally, telemedicine and remote healthcare solutions have gained prominence, enabling improved access to diagnosis and treatment for CRS patients. However, supply chain disruptions and economic uncertainties have impacted the market, with some patients facing difficulties in accessing care. Overall, the post-COVID era calls for continued innovation, collaboration, and patient-centric approaches to tackle the challenges in the CRS market.

Companies considered and profiled in this market study

Key market companies studied and profiled for this research include AstraZeneca, Bayer AG, Ivax Pharmaceuticals, Pfizer, Novartis Pharmaceuticals Corporation, Sanofi, Sunovion Pharmaceuticals, Cipla, Smith & Nephew, Medtronic, SinuSys Corporation, Olympus Corporation, and Acclarent, among other companies .

The players operating in the market have undertaken a number of strategies related to the market in the period 2017-2020. The key highlight is:

• In August 2020, the European Commission (EC) approved Xolair (Omalizumab) manufactured by Novartis. The product is developed to treat severe chronic rhinosinusitis with nasal polyps. This approval is likely to bolster the product's safety and efficacy records
• In June 2019, Sanofi's Regeneron Pharmaceuticals and Dupixent (Dupilumab) were approved by the United States Food and Drug Administration (FDA). This drug is developed for adults with poorly controlled chronic rhinosinusitis with nasal polyposis

Scope of Research

Segments Covered in Report

This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the market trends in each of the sub-segments from 2018 to 2030. The scope of the report can be defined as:

Pharmanucleushave segmented Chronic Rhinosinusitis Market on the basis of product, disease type, distribution channel and region:

• Product Outlook (Revenue in Million USD; 2017–2030)
  • Steroids
    1. Topical Nasal Steroid
    2. Systemic Steroids
  • Nasal Irrigation
    1. Hypertonic and Isotonic Saline
    2. Steroid Nasal Irrigation
    3. Topical Antibiotic Therapy
  • Surgical Based
    1. Ethmoidectomy
    2. Endoscopic Intranasal Intervention
    3. Others
  • Antibiotics
    1. Amoxicillin-Clavulanate
    2. Clindamycin
    3. Sulfamethoxazole
    4. Levofloxacin
  • Macrolide Therapy
  • Antifungal Therapy

• Disease Outlook (Revenue in Million USD; 2017–2030)
  • Anatomical Differences
  • Nasal Tumors
  • Mucosal Edema
  • Non-Allergic Rhinitis
  • Immune Deficiency
  • Other

• Distribution Channel (Revenue in Million USD; 2017–2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Other

• Regional Outlook (Revenue in Million USD; 2017–2030)
  • North America
    1. U.S
    2. Canada
  • Europe
    1. Germany
    2. UK
    3. France
    4. Spain
    5. Italy
    6. Rest of the Europe
  • Asia Pacific
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America
    1. Brazil